Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Pediatr Infect Dis J ; 37(9): 901-907, 2018 09.
Artigo em Inglês | MEDLINE | ID: mdl-29561517

RESUMO

BACKGROUND: Although Italian pediatric antimicrobial prescription rates are among the highest in Europe, little action has been taken to improve the appropriateness of antimicrobial prescriptions. The primary aim of this study was to assess changes in antibiotic prescription before and after acute otitis media (AOM) and group A streptococcus (GAS) pharyngitis Clinical Pathway (CP) implementation; secondary aims were to compare treatment failures and to assess change in the total antibiotics costs before and after CP implementation. METHODS: Pre-post quasi-experimental study comparing the 6-month period before CP implementation (baseline period: October 15, 2014, through April 15, 2015) to the 6 months after intervention (postintervention: October 15, 2015, through April 15, 2016). RESULTS: Two hundred ninety-five pre- and 278 postintervention emergency department visits were associated with AOM. After CP implementation, there was an increase in "wait and see" approach and a decrease in overall prescription of broad-spectrum antibiotics from 53.2% to 32.4% (P < 0.001). One hundred fifty-one pre- and 166 postimplementation clinic visits were associated with GAS pharyngitis, with a decrease in broad-spectrum prescription after CP implementation (46.4% vs. 6.6%; P < 0.001). For both conditions, no difference was found in treatment failure, and total antibiotics cost was significantly reduced after CP implementation, with a decrease especially in broad-spectrum antibiotics costs. CONCLUSIONS: A reduction in broad-spectrum antibiotic prescriptions and a reduction in the total cost of antibiotics for AOM and GAS pharyngitis along with an increase in "wait and see" prescribing for AOM indicate effectiveness of CP for antimicrobial stewardship in this setting.


Assuntos
Antibacterianos/uso terapêutico , Procedimentos Clínicos , Prescrições de Medicamentos/estatística & dados numéricos , Otite Média/tratamento farmacológico , Faringite/tratamento farmacológico , Falha de Tratamento , Doença Aguda , Adolescente , Antibacterianos/economia , Gestão de Antimicrobianos/economia , Criança , Pré-Escolar , Serviço Hospitalar de Emergência/estatística & dados numéricos , Feminino , Humanos , Lactente , Itália , Masculino , Otite Média/microbiologia , Faringite/microbiologia , Padrões de Prática Médica/estatística & dados numéricos , Streptococcus pyogenes/efeitos dos fármacos
2.
World J Nephrol ; 5(2): 220-3, 2016 Mar 06.
Artigo em Inglês | MEDLINE | ID: mdl-26981448

RESUMO

Comamonas testosteroni (C. testosteroni) has been rarely observed as an infectious agent in clinical practice. Few reports described its potential pathogenicity in bloodstream and abdominal infections. Here, we report our experience in the treatment of a C. testosteroni-associated peritonitis in a four-year-old girl receiving chronic peritoneal dialysis (PD). The organism was shown to be highly susceptible to appropriate antibiotic therapy. Infection responded promptly and the patient was managed conservatively without withdrawal from PD.

3.
Pediatrics ; 131(1): e309-12, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23209099

RESUMO

This case report describes a preterm newborn infant who was treated with a single dose of rasburicase for an increase in uric acid level. He died on the third day as a result of complications of hemolysis, which appeared to be precipitated by rasburicase. The patient's death was preceded by progressive respiratory insufficiency, lactic acidosis, and hyperbilirubinemia, culminating in refractory hypoxia and hypotension. A postmortem assay for glucose-6-phosphate dehydrogenase showed deficiency and the glucose-6-phosphate dehydrogenase Mediterranean genotype.


Assuntos
Recém-Nascido Prematuro/metabolismo , Urato Oxidase/administração & dosagem , Urato Oxidase/efeitos adversos , Evolução Fatal , Hemólise/efeitos dos fármacos , Hemólise/fisiologia , Humanos , Recém-Nascido , Recém-Nascido Prematuro/sangue , Recém-Nascido Prematuro/urina , Masculino
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...